Little, Dustin J.
Arnold, Matthew
Hedman, Katarina
Sun, Ping
Haque, Syed Asif
James, Glen
Funding for this research was provided by:
AstraZeneca
Article History
Received: 12 September 2022
Accepted: 17 March 2023
First Online: 5 April 2023
Declarations
:
: This study was performed in accordance with ethical principles consistent with the Declaration of Helsinki, International Conference on Harmonization, Good Clinical Practice, and the applicable legislation on noninterventional studies and observational studies. This study used de-identified data from the CPRD and did not require data collection beyond that of routine clinical care. No identifiable information was collected or examined as part of the study. Ethical and scientific approval for use of CPRD data in the current study was obtained from the Independent Scientific Advisory Committee of CPRD (protocol number: 19_172). Informed consent was waived by the East Midlands – Derby Research Ethics Committee because CPRD data are anonymized for research purposes (for further information, see: ExternalRef removed).
: Not applicable.
: DJL, MA, KH, PS, and SAH are employees and stockholders of AstraZeneca. GJ was an employee and stockholder of AstraZeneca at the time of manuscript preparation. The results in this manuscript have not been published previously in whole or part.